P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia

Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives

(2016) Michele Malagola et al.   ANNALS OF HEMATOLOGY

Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence

(2016) Kirsten Bleckmann et al.   BRITISH JOURNAL OF HAEMATOLOGY

miRNA-126 Orchestrates an Oncogenic Program in B Cell Precursor Acute Lymphoblastic Leukemia

(2016) Silvia Nucera et al.   CANCER CELL

Clinical updates in adult acute lymphoblastic leukemia

(2016) Omar Al Ustwani et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pharmacological activation of wild-type p53 in the therapy of leukemia

(2016) Kensuke Kojima et al.   EXPERIMENTAL HEMATOLOGY

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients

(2016) S Soverini et al.   LEUKEMIA

Therapy for relapsed acute lymphoblastic leukemia: Still a role for standard chemotherapy regimens?

(2016) Karen Seiter   LEUKEMIA RESEARCH

New monoclonal antibodies for the treatment of acute lymphoblastic leukemia

(2016) Nosha Farhadfar et al.   LEUKEMIA RESEARCH

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

(2016) Sébastien Maury et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program

(2016) Min H. Kang et al.   PEDIATRIC BLOOD & CANCER

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

(2016) Aharon Ronson et al.   Current Oncology Reports

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia

(2016) Xavier Thomas et al.   Drug Design Development and Therapy

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients

(2016) Stefania Trino et al.   Oncotarget

The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies

(2016) Victor D. Fedorov et al.   Current Hematologic Malignancy Reports

Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia

(2016) Ajoy Dias et al.   Current Hematologic Malignancy Reports

Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

(2016) B. Reis et al.   HAEMATOLOGICA

Clinical Overview of MDM2/X-Targeted Therapies

(2016) Andrew Burgess et al.   Frontiers in Oncology

How I treat acute lymphoblastic leukemia in older adolescents and young adults

(2015) E. Curran et al.   BLOOD

Monoclonal antibodies in acute lymphoblastic leukemia

(2015) E. Jabbour et al.   BLOOD

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Effective Targeting of the P53-MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia

(2015) J. Richmond et al.   CLINICAL CANCER RESEARCH

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

(2015) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

microRNA-181a enhances cell proliferation in acute lymphoblastic leukemia by targeting EGR1

(2015) Lorena Verduci et al.   LEUKEMIA RESEARCH

Acute Lymphoblastic Leukemia in Children

(2015) Stephen P. Hunger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma

(2015) M F Riley et al.   ONCOGENE

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation

(2015) Gautam Borthakur et al.   PLoS One

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells

(2015) Bing Z. Carter et al.   Oncotarget

MDM2-Mediated Degradation of p14ARF: A Novel Mechanism to Control ARF Levels in Cancer Cells

(2015) Maria Vivo et al.   PLoS One

ARF tumor suppression in the nucleolus

(2014) Leonard B. Maggi et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis

(2014) A. Stengel et al.   BLOOD

p53 haploinsufficiency and functional abnormalities in multiple myeloma

(2014) P J Teoh et al.   LEUKEMIA

Inhibition of MDM2 by Nilotinib Contributes to Cytotoxicity in Both Philadelphia-Positive and Negative Acute Lymphoblastic Leukemia

(2014) Hailong Zhang et al.   PLoS One

Inhibition of the MDM2 E3 Ligase Induces Apoptosis and Autophagy in Wild-Type and Mutant p53 Models of Multiple Myeloma, and Acts Synergistically with ABT-737

(2014) Dongmin Gu et al.   PLoS One

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

(2013) A. K. Fielding et al.   BLOOD

Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer

(2013) Tom Van Maerken et al.   CANCER LETTERS

Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

(2013) Fedor Kryukov et al.   GENOMICS

TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy

(2013) S. Chiaretti et al.   HAEMATOLOGICA

Targeting p53 by small molecules in hematological malignancies

(2013) Manujendra N Saha et al.   Journal of Hematology & Oncology

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia

(2013) U Kaindl et al.   LEUKEMIA

The genomic landscape of hypodiploid acute lymphoblastic leukemia

(2013) Linda Holmfeldt et al.   NATURE GENETICS

p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo

(2013) Oleg Timofeev et al.   Cell Reports

Stochastic and Deterministic Models of Cellular p53 Regulation

(2013) Gerald B. Leenders et al.   Frontiers in Oncology

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

(2012) Andrea Biondi et al.   LANCET ONCOLOGY

Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer

(2012) A. Naccarati et al.   MUTAGENESIS

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

(2012) Hernan Carol et al.   PEDIATRIC BLOOD & CANCER

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2011) R. Foa et al.   BLOOD

CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients

(2011) I. Iacobucci et al.   CLINICAL CANCER RESEARCH

Analysis of p53 Tumor Suppressor Pathway Genes in Chronic Lymphocytic Leukemia

(2011) Mustafa Isin et al.   DNA AND CELL BIOLOGY

Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia

(2011) Jana Hof et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia

(2011) Amaia Vilas–Zornoza et al.   PLoS One

p53 at a glance

(2010) C. A. Brady et al.   JOURNAL OF CELL SCIENCE

Paradoxical suppression of cellular senescence by p53

(2010) Z. N. Demidenko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

p53 and MDM2: Antagonists or Partners in Crime?

(2009) Christine M. Eischen et al.   CANCER CELL

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

(2008) L Gu et al.   LEUKEMIA

CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults—An array CGH study

(2008) Anu Usvasalo et al.   LEUKEMIA RESEARCH

Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells

(2008) N. Zhu et al.   MOLECULAR CANCER THERAPEUTICS